Page 3 of 13
Egypt Explores Needle-Free Vaccine Delivery
Egypt is set to explore the use of needle-free injections for polio immunisation, following a new agreement between US-based medical technology firm PharmaJet, local manufacturer EVA Pharma, and the Egyptian Unified Procurement Authority (UPA).
August 4, 2025
PharmaJet® Enters into MOU Agreement with Egyptian UPA and EVA Pharma to provide Needle-free Delivery for Routine Immunization in Egypt
GOLDEN, Colo., CAIRO, Egypt — July 10, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Memorandum of Understanding (MOU) agreement with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, to explore the integration of needle-free delivery of inactivated polio vaccine into Egypt’s routine immunization program.
July 9, 2025
Immuno Cure and PharmaJet advance novel HIV therapeutic DNA vaccine using needle-free technology in humans
Immuno Cure BioTech, a clinical-stage biotechnology startup based in Hong Kong Science Park, has announced its upcoming collaboration with PharmaJet® to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, delivered via PharmaJet’s innovative Tropis® needle-free injection system in a clinical study.
Uncategorized
June 19, 2025
Innovating polio immunization: evaluating needle-free delivery in Nigeria
A recent study published in Vaccines explores the impact of needle-free delivery of fractional dose inactivated polio vaccine (fIPV) on Nigeria’s routine immunization program. The research assesses the feasibility, cost-effectiveness, and impact of using a WHO-prequalified, intradermal needle-free device, Tropis®, for fIPV administration.
PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine
GOLDEN, Colo. — June 19, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has entered into an agreement with Immuno Cure, a prominent developer of DNA vaccines. Under the terms of the agreement, Immuno Cure will use PharmaJet’s Tropis ID system in a human clinical trial to deliver their novel HIV-1 therapeutic DNA Vaccine (ICVAX). The agreement was executed on June 16, 2025, during a signing ceremony at the 2025 BIO International Convention in Boston, Massachusetts.
Evaluating the Impact of Needle-Free Delivery of Inactivated Polio Vaccine on Nigeria’s Routine Immunization Program: An Implementation Hybrid Trial
The Tropis® ID device (PharmaJet®), a needle-free injection system, is a World Health Organization prequalified, hand-held device, which delivers intradermal injections without the use of needles and has previously been used for the delivery of fractional doses of inactivated polio vaccine (fIPV) in campaign and house-to-house settings. This implementation research study aimed to comparatively evaluate…
June 3, 2025
Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care
GOLDEN, Colo. — June 5, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial.1 The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months.
Study in Nigeria shows needle-free injection of IPV is effective at increasing coverage, decreasing program costs
A study in Nigeria has found that needle-free, intradermal delivery of the inactivated polio vaccine (IPV) has the potential to significantly improve vaccination coverage and reduce costs in routine immunization programs. The findings offer a promising path forward for strengthening polio eradication efforts and expanding access to immunization in resource-limited settings.
May 5, 2025
Publication in Vaccine Highlights Fewer Adverse Events with PharmaJet Needle-free Intradermal Delivery compared to Needle and Syringe
GOLDEN, Colo. — May 1, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, today announced the publication of a study demonstrating the benefits of PharmaJet Tropis needle-free system compared with N/S for ID administration of fractional dose poliovirus vaccine (fIPV). The study entitled Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba is published in Vaccine.1
April 21, 2025
PharmaJet® Presents Partner Data Demonstrating that Needle-free Delivery Boosts Immune Response of DNA and Novel Therapeutic Cancer Vaccines
GOLDEN, Colo. — April 17, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present insights from several DNA Cancer Vaccine partner trials using PharmaJet’s Precision Delivery Systems™ at the World Vaccine Congress 2025 on April 23, 2025 at 12:25 PM ET.
Tags: Cancer, DNA, Events, Tropis/Stratis
April 14, 2025
Needle-free Polio Vaccinations Reduce Cost and Increase Uptake
(Vax-Before-Travel News)
As the world is confronted with an increasing number of countries reporting polio cases and poliovirus detections, an innovative vaccination strategy has been launched in polio hot spots.
March 31, 2025
Publication in npj Vaccines Reports Cross-reactive and Long-Lasting Immune Responses for self-amplifying mRNA (samRNA) COVID-19 Vaccine Booster Administered Intradermally with PharmaJet Tropis®
GOLDEN, Colo. — April 2, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, today announced the npj Vaccines publication of Gennova Biopharmaceutical’s post hoc analysis of their Phase 3 clinical study, which evaluated the cellular immune breadth induced by their self-amplifying (samRNA) vaccine (GEMCOVAC-OM) administered as a booster with Tropis ID.
Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba
2025 Resik, S et al Fractional-dose inactivated poliovirus vaccine (fIPV), 1/5th of a standard IPV dose, is used in Cuba’s routine immunization (RI) schedule.
Tags: Inactivated, Polio, Tropis
March 11, 2025
Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19
2025 Kumar, D et al Selecting a booster vaccine strategy that generates cellular immune breadth is crucial for effectively recalling cellular reservoirs upon infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants.
WHO Deploys Tropis®, PharmaJet’s Needle-free Injection System in Latest Polio Eradication Campaign in Pakistan
GOLDEN, Colo. — March 13, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that their Tropis intradermal (ID) delivery system was used in the latest World Health Organization’s (WHO) polio eradication campaign in Pakistan in February 2025. The supplemental immunization activity (SIA) campaign for children between 4 and 59 months of age was implemented in two regions in the Quetta block (Pishin, Quetta, Kila Abdullah, and Chaman) and Karachi (Central Karachi, East, East-Gujro, Keamari, Korangi, Malir, and West). Tropis was used to deliver fractional dose inactivated polio vaccine (fIPV) in parallel to oral polio vaccine (OPV) administration as part of a WHO recommended strategy to boost humoral immunity.
PharmaJet to Highlight Benefits of Needle-free Intradermal Delivery at Medical Conference in Ethiopia
GOLDEN, Colo. — February 19, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share the latest routine immunization study results at the 61st Annual Medical Conference and International Health Exhibition to be held on February 21-22, 2025 at the Haile Grand in Addis Ababa, Ethiopia.
February 20, 2025
Oncology
What if your delivery system could improve the effectiveness of your cancer therapeutic? Talk to an Expert Enabling New Possibilities for Your Cancer Therapeutic PharmaJet technology enables improved tissue distribution and cellular uptake of vaccines. 1, 2, 3 DNA vaccines delivered needle-free tend to elicit improved immunogenicity compared with needles. 2, 4, 5, 6, 7,...
January 17, 2025
Publication in NPJ Vaccines Highlights Benefits of Stratis® Intramuscular Delivery of DNA Vaccine for Hantaviruses
GOLDEN, Colo. — December 10, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced the publication in NPJ Vaccines of the US Army Medical Research Institute of Infectious Diseases (USAMRIID) Phase 1 clinical trial to evaluate the safety and immunogenicity of its plasmid DNA Hantavirus vaccines administered with the Stratis IM System. The study reported that two of the three plas-mid DNA vaccines tested are safe and immunogenic in human subjects. Given these positive Phase 1 results the Hantaan and Puumala vaccines delivered with Stratis IM are being included in an ongoing Phase 2a clinical trial.
Tags: DNA, Infectious Diseases, Stratis
December 9, 2024
Poster Presentation at International mRNA Health Conference Showcases Clinical Evidence that PharmaJet® Delivery Systems Enable mRNA Vaccine Delivery
GOLDEN, Colo. — November 12, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced their upcoming poster presentation on November 13, 2024 at the International mRNA Health Conference 2024. The PharmaJet poster (#32), entitled Modulating Immune Responses to mRNA Vaccines Using Needle-Free Delivery Technologies, will be presented by Dr. Carmen Ledesma-Feliciano, DVM, PhD, DACLAM, Scientific Affairs Manager, PharmaJet. The conference brings together industry and academic professionals to explore the rapidly advancing science and business of mRNA medicines and features poster presentations highlighting the latest advancements in mRNA technology.
Tags: COVID-19, mRNA, Other, Rabies, Tropis/Stratis
November 9, 2024
PharmaJet Poster Presentation at Cancer Immunotherapy Conference Highlights How Needle-free Technology is Enhancing Oncology Solutions
GOLDEN, Colo. — November 5, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced their upcoming poster presentation on November 8, 2024 at the Society of Immunotherapy of Cancer (SITC) conference. The poster (#741), entitled Modulating Immune Responses to Therapeutic Cancer Vaccines through Precision Delivery Technologies, will be presented by Gregg Wilson, PhD, RN, Director of Medical and Scientific Affairs, PharmaJet. The SITC conference will be held at the George R. Brown Convention Center in Houston, Texas, bringing together leading cancer immunotherapy researchers, clinicians, scientists and industry leaders in the oncology field.
Tags: Cancer, DNA, Other, Stratis
November 1, 2024
Page 3 of 13